Personalized ATG with or without verapamil for new type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new way to give a medicine called anti-thymocyte globulin (ATG) with or without verapamil, a blood pressure drug. It aims to slow down the loss of insulin-making cells in people newly diagnosed with type 1 diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 6 and 35 years old.
- You must have been diagnosed with type 1 diabetes in the last 100 days.
- Your body must still make some insulin (a test called C-peptide measures this).
- You must be willing to get a flu shot if it's flu season, and avoid live vaccines during the study.
- You must not have a weak immune system, active infections, or certain medical conditions like heart disease or blood disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two different medications (Anti-Thymocyte Globulin and Adalimumab or Verapamil) to see if they can slow down the loss of insulin production in people with newly diagnosed type 1 diabetes. Participants will be randomly assigned to receive one of the treatments and will be followed for about a year to see how well their bodies still make insulin.
This study tests if verapamil (a common blood pressure medication) can help children newly diagnosed with type 1 diabetes keep making their own insulin for longer. It aims to preserve the body's own insulin-producing cells, which may reduce the amount of insulin injections needed.
This Phase 2 study tests whether starting with cyclosporine and then giving low-dose IL-2 can better protect the body’s insulin-producing function after type 1 diabetes is diagnosed. It’s meant for people diagnosed very recently who have specific diabetes-related immune markers.
This trial compares two medicines, teplizumab and ATG, to see if they can delay or prevent type 1 diabetes from progressing to needing insulin. It is for people ages 4 to 35 who have early signs of diabetes (stage 2) and specific autoantibodies.
This trial tests a new combination treatment for children who have been diagnosed with stage 1 type 1 diabetes, meaning they have some markers but do not yet need insulin. The treatment uses special immune cells (Treg cells) and an antibody (anti-CD20) to try to preserve the body's ability to make insulin.
This study tests an immune-suppressing medicine (anti-thymocyte globulin) in people with type 1 diabetes to see if it can help save the body's ability to make insulin. It is for people aged 5–40 who were diagnosed recently or have had diabetes for up to 2 years.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.